Clinical testing laboratories, hospitals, and research institutions require quality hematology analyzers and reagents for conducting tests to diagnose diseases such as infections, anemia, viruses, diabetes, genetic problems, and cancer. Labs can choose from fully automated and semi-automated analyzers with the ability to regulate plasma drug level for both therapeutic and illicit drugs.
In its new Hematology Analyzer and Reagent Market analysis report 2015-2021, Persistent Market Research predicts that Asia will be the fastest growing market in the next five years. The study identifies the factors which will drive the market growth in this region as:
- Developing healthcare infrastructure
- Increasing funding towards the development of hematology products in this region
- Rising awareness about better healthcare and
- A large patient population base
Currently, North America dominates the market due to the regions’ high disposable income and increasing adoption of automated hematology instruments by diagnostics laboratories.
In general, the growth of the global hematology analyzer and reagent market is driven by the increasing adoption of automated hematology instruments, rising technological advancements, integration of basic flow-cytometry techniques in modern analyzers, rising demand for high-throughput hematology analyzers, and development of high-sensitivity point-of-care (POC) hematology testing. However, factors such as the high cost of analyzers, safety and quality of devices, intense competition among existing players and stringent and time-consuming regulatory policies for hematology instruments restrain market growth.
The study also indicate that several conditions could open up opportunities for new players in the market such as the use of microfluidics technology in analyzers, introduction of digital imaging systems in hematology laboratories, and increasing focus on emerging markets such as India and China.
Key players in the market include Sysmex Corporation, Abbott Laboratories, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Mindray Medical International Limited, Siemens Healthcare, HORIBA, Ltd. and Nihon Kohden Corporation.